1. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева Л.И., Бирюкова Е.В., Гребенникова Т.А., Дзеранова Л.К., Древаль А.В., Загородний Н.В., Ильин А.В., Крюкова И.В., Лесняк О.М., Мамедова Е.О., Никитинская О.А., Пигарова Е.А., Родионова С.С., Скрипникова И.А., Тарбаева Н.В., Фарба Л.Я., Цориев Т.Т., Чернова Т.О., Юренева С.В., Якушевская О.В., Дедов И.И. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы Эндокринологии, 2017, Том 63, N 6, стр. 392 - 426.
2. Camacho P.M., Petak S.M., Binkley N., Clarke B.L., Harris S.T., Hurley D.L., Kleerekoper M., Lewiecki E.M., Miller P.D., Narula H.S., Pessah-Pollack R., Tangpricha V., Wimalawansa S.J., Watts N.B.: American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016 Sep 2; 22 (Suppl 4): 1 - 42.
3. Kanis J.A., Cooper C., Rizzoli R., Reginster J.Y.; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan; 30(1): 3 - 44. doi: 10.1007/s00198-018-4704-5.
4. Raman-Wilms L. Book Review: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Annals of Pharmacotherapy. 1999; 33(12): 1377 - 1378. doi: 10.1177/106002809903301207.
5. American Association of Orthopedic Surgeon Position Statement, 1159, December 2009.
6. Kanis J.A., on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaboraiting Centre, University of Sheffield, UK, 2008.
7. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun; 94(6): 646 - 50. DOI: 10.1016/0002-9343(93)90218-e.
8. Михайлов Е.Е., Беневоленская Л.И. Руководство по остеопорозу. М.: БИНОМ. Лаборатория знаний; 2003.
9. Лесняк О.М., Ершова О.Б. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии 2010. Naturaprint; 2011.
10. Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я.: "Остеопороз - от редкого симптома эндокринных болезней до безмолвной эпидемии 20 - 21 века" Ж. Проблемы Эндокринологии, 2011, том 57, стр. 35 - 45.
11. Ершова О.Б., Белова К.Ю., Белов М.В., Ганерт О.А., Гладкова Е.Н., Ходырев В.Н., Лесняк О.М., Давтян В.Г., Пилюкова Р.И., Романова М.А., Синицина О.С. Эпидемиология переломов проксимального отдела бедренной кости у городского населения Российской Федерации: результаты многоцентрового исследования. Форум остеопороза, 23 - 25 сентября, 2012; Санкт-Петербург. Материалы научно-практической конференции "Остеопороз - важнейшая мультидисциплинарная проблема здравоохранения XXI века"; 23 - 27.
12. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования). Остеопороз и остеопатии. 2002; 1: 8 - 11.
13. Добровольская О.В., Торопцова Н.В., Лесняк О.М. Экономические аспекты осложненного остеопороза: стоимость лечения в течение первого года после перелома. Современная ревматология. 2016;. т. 10. N 3. с. 29 - 34.
14. Бахтиярова С.А., Бортник С.Б., Лесняк О.М., Кузнецова Н.Л. Сравнительная оценка социальных последствий перелома проксимального отдела бедра и инфаркта миокарда у пациентов старшего возраста. Остеопороз и остеопатии. 2003; Приложение. Научная программа и тезисы Росс. Конгресса по остеопорозу, Москва, 20 - 22 октября 2003 г. - С. 45.
15. Lesnyak O., Ershova O., Belova K. et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012; 7(1-2): 67 - 73. doi: 10.1007/s11657-012-0082-3.
16. Cosman F., de Beur S., LeBoff M., de Beur S.J., Tanner B. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation. 1150 17th St., NW, Suite 850, Washington, DC 20036, Release Date: April 1, 2014.
17. Shepstone L., Lenaghan E., Cooper C., et al. SCOOP Study Team. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018 Feb 24; 391(10122): 741 - 747. doi: 10.1016/S0140-6736(17)32640-5.
18. Turner D.A., Khioe R.F.S., Shepstone L., et al. SCOOP Study Team. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. J Bone Miner Res. 2018 May; 33(5): 845 - 851. doi: 10.1002/jbmr.3381.
19. Hippisley-Cox J., Coupland C. (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractures Scores. Br Med J 339: b4229.
20. Hoff M., Meyer H.E., Skurtveit S. et al (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporos Int 28: 2935 - 2944.
21. Fraser L-A, Langsetmo L., Berger C. et al (2011) Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int 22: 829 - 837.
22. Leslie W.D., Lix L.M., Johansson H. et al (2010) Manitoba bone density program. Independent clinical validation of a Canadian FRAX((R)) tool: fracture prediction and model calibration. J Bone Miner Res 25: 2350 - 2358.
23. Jiang X., Gruner M., Tremollieres F., Pluskiewicz W., Sornay-Rendu E., Adamczyk P., Schnatz P.F. Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: A systematic review and meta-analysis. Bone. 2017 Jun; 99: 20 - 25. doi: 10.1016/j.bone.2017.02.008.
24. Marques A., Ferreira R.J., Santos E., Loza E., Carmona L., da Silva J.A. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Nov; 74(11): 1958 - 67. doi: 10.1136/annrheumdis-2015-207907.
25. Kanis J., Johnell O., Oden A., Johansson H., McCloskey E. FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporosis International. 2008; 19(4): 385 - 397. doi: 10.1007/s00198-007-0543-5.
26. Lindsay R., Silverman S.L., Cooper C., Hanley D.A., Barton I., Broy S.B., et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285: 320 - 323.
27. Gehlbach S., Saag K.G., Adachi J.D., Hooven F.H., Flahive J., Boonen S., et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012; 27: 645 - 653.
28. Edwards B.J., Bunta A.D., Simonelli C., Bolander M., Fitzpatrick L.A. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007; 461: 226 - 230.
29. Ross P. Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women. Annals of Internal Medicine. 1991; 114(11): 919. doi: 10.7326/0003-4819-114-11-919.
30. Gallagher J., Genant H., Crans G., Vargas S., Krege J. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures. The Journal of Clinical Endocrinology & Metabolism. 2005; 90(3): 1583 - 1587. doi: 10.1210/jc.2004-0826.
31. Marcus R., Wang O., Satterwhite J, Mitlak B. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2003; 18(1): 18 - 23. doi: 10.1359/jbmr.2003.18.1.18.
32. Kanis J.A., Barton I., Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 2005; 16: 475 - 82.
33. Johnell O., Kanis J.A., Black D.M., et al. Association between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Bone Miner Res 2004; 19: 64 - 72.
34. Kanis J.A., Jonsson B., Oden A., McCloskey E.V. A metaanalysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX. Osteoporos Int 2011; 22: 2347 - 55.
35. Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35(2): 375 - 82.
36. Klotzbuecher C.M., Ross P.D., Landsman P.B., et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Mineral Research 2000; 15(4): 721 - 39.
37. Schousboe J., Ensrud K., Nyman J., Kane R., Melton L. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis International. 2005; 16(12): 1883 - 1893. doi: 10.1007/s00198-005-1956-7.
38. Gallagher J.C., Sai A.J. Bone: Is screening for secondary causes of osteoporosis worthwhile? Nat Rev Endocrinol. 2010; 6: 360 - 362.
39. Barzel U.S. Recommended testing in patients with low bone density. J Clin Endocrinol Metab. 2003; 88: 1404 - 1405.
40. Tannenbaum C., Clark J., Schwartzman K., Wallenstein S., Lapinski R., Meier D., et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002; 87: 4431 - 4437.
41. Cerda Gabaroi, D. et al. search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 17, 135 - 139 (2010).
42. Deutschmann, H.A. et al. search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density. J. Intern. Med. 252, 389 - 397 (2002).
43. Priemel, M. et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res. 25, 305 - 312 (2009).
44. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18: 1051 - 1056.
45. Hochberg M.C., Greenspan S., Wasnich R.D. et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metabol. 2002; 87(4): 1586 - 1592. doi: 10.1210/jcem.87.4.8415.
46. Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New Engl. J. Med. 2004; 350(12): 1189 - 99. doi: 10.1056/NEJMoa030897.
47. Black D.M., Schwartz A.V., Ensrud K.E. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized tri-al. J. Am. Med. Association. 2006; 296(24): 2927 - 38. doi: 10.1001/jama.296.24.2927.
48. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J. (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11 (Suppl 6): S2-17.
49. Vasikaran S., Eastell R., Bruyere O., Foldes A.J., Garnero P., Griesmacher A., McClung M., Morris H.A., Silverman S., Trenti T., Wahl D.A., Cooper C., Kanis J.A. (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22: 391 - 420.
50. Johansson H., Oden A., Kanis J.A., McCloskey E.V., Morris H.A., Cooper C., Vasikaran S. (2014) A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int 94: 560 - 567.
51. Bauer D.C., Black D.M., Bouxsein M.L., Lui L.Y., Cauley J.A., de Papp A.E., Grauer A., Khosla S., McCulloch C.E., Eastell R.; Foundation for the National Institutes of Health (FNIH) Bone Quality Project. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. J Bone Miner Res. 2018 Apr; 33(4): 634 - 642. doi: 10.1002/jbmr.3355. Epub 2018 Jan 10.
52. Ravn P., Hosking D., Thompson D. et al. Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study1. The Journal of Clinical Endocrinology & Metabolism. 1999; 84(7): 2363 - 2368. doi: 10.1210/jcem.84.7.5847.
53. Fink E., Cormier C., Steinmetz P., Kindermans C., Le Bouc Y., Souberbielle J. Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy. Osteoporosis International. 2000; 11(4): 295 - 303. doi: 10.1007/pl00004183.
54. Bauer D., Black D., Garnero P. et al. Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial. J Bone Miner Res. 2004; 19(8): 1250 - 1258. doi: 10.1359/jbmr.040512.
55. Delmas P., Recker R., Chesnut C. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis International. 2004; 15(10). doi: 10.1007/s00198-004-1602-9.
56. Reginster J., Gieschke R. Clinical Utility of a Pharmacostatistical Model for Ibandronate in Postmenopausal Osteoporosis. CDM. 2006; 7(7): 827 - 836. doi: 10.2174/138920006778520624.
57. Krege J., Lane N., Harris J., Miller P. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporosis International. 2014; 25(9): 2159 - 2171. doi: 10.1007/s00198-014-2646-0.
58. Imaz I., Zegarra P., Gonzalez-Enriquez J., Rubio B., Alcazar R., Amate J. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporosis International. 2009; 21(11): 1943 - 1951. doi: 10.1007/s00198-009-1134-4.
59. Bergmann P., Body J., Boonen S. et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. International Journal of Clinical Practice. 2009; 63(1): 19 - 26. doi: 10.1111/j.1742-1241.2008.01911.x.
60. Burch J., Rice S., Yang H. et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technology Assessment. 2014; 18(11). doi: 10.3310/hta18110.
61. Dresner-Pollak R., Parker R., Poku M., Thompson J., Seibel M., Greenspan S. Biochemical Markers of Bone Turnover Reflect Femoral Bone Loss in Elderly Women. Calcified Tissue International. 1996; 59(5): 328 - 333. doi: 10.1007/s002239900135.
62. Ross PKnowlton W. Rapid Bone Loss Is Associated with Increased Levels of Biochemical Markers. J Bone Miner Res. 1998; 13(2): 297 - 302. doi: 10.1359/jbmr.1998.13.2.297.
63. Hansen M.A., Overgaard K., Riis B.J. et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991; 303: 961 - 4.
64. Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P. Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study. J Bone Miner Res. 1999; 14(9): 1614 - 1621. doi: 10.1359/jbmr.1999.14.9.1614.
65. Tian, A., Ma, J., Feng, K. et al. Reference markers of bone turnover for prediction of fracture: a meta-analysis. J Orthop Surg Res 14, 68 (2019). https://doi.org/10.1186/s13018-019-1100-6.
66. Schousboe J., Bauer D., Nyman J., Kane R., Melton L., Ensrud K. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporosis International. 2006; 18(2): 201 - 210. doi: 10.1007/s00198-006-0218-7.
67. Boonen S., Body J., Boutsen Y. et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis International. 2005; 16(3): 239 - 254. doi: 10.1007/s00198-004-1812-1.
68. McNabb B., Vittinghoff E., Schwartz A. et al. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res. 2013; 28(6): 1319 - 1327. doi: 10.1002/jbmr.1864.
69. Bauer D., Schwartz A., Palermo L. et al. Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy. JAMA Internal Medicine. 2014; 174(7): 1126.
70. Cosman F., Cauley J., Eastell R. et al. Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. The Journal of Clinical Endocrinology & Metabolism. 2014; 99(12): 4546 - 4554. doi: 10.1210/jc.2014-1971.
71. Bauer D., Garnero P., Hochberg M. et al. Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial. J Bone Miner Res. 2005; 21(2): 292 - 299. doi: 10.1359/jbmr.051018.
72. Seibel M., Naganathan V., Barton I., Grauer A. Relationship Between Pretreatment Bone Resorption and Vertebral Fracture Incidence in Postmenopausal Osteoporotic Women Treated With Risedronate. J Bone Miner Res. 2003; 19(2): 323 - 329. doi: 10.1359/jbmr.0301231.
73. Yamamoto T., Tsujimoto M., Hamaya E., Sowa H. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 mg/day administered subcutaneously in Japanese patients with osteoporosis. J. Bone Miner. Metab. 2013; 31: 199 - 205. doi: 10.1007/s00774-012-0403-z
74. Kanis J., Melton L., Christiansen C., Johnston C., Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 2009; 9(8): 1137 - 1141. doi: 10.1002/jbmr.5650090802.
75. Nevitt M.C., Ettinger B., Black D.M., Stone K., Jamal S.A., Ensrud K., Segal M., Genant H.K., Cummings S.R. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998 May 15; 128(10): 793 - 800. doi: 10.7326/0003-4819-128-10-199805150-00001.
76. Yamamoto M., Yamaguchi T., Yamauchi M., Kaji H., Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009 Apr; 24(4): 702 - 9. doi: 10.1359/jbmr.081207.
77. Siminoski K., Jiang G., Adachi J.D., Hanley D.A., Cline G., Ioannidis G., Hodsman A., Josse R.G., Kendler D., Olszynski W.P., Ste Marie L.G., Eastell R. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int. 2005 Apr; 16(4): 403 - 10. doi: 10.1007/s00198-004-1709-z. Epub 2004 Aug 11.
78. T.P. van Staa, H.G.M. Leufkens, L. Abenhaim, B. Zhang, C. Cooper, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatology, Volume 39, Issue 12, December 2000, Pages 1383 - 1389, https://doi.org/10.1093/rheumatology/39.12.1383
79. Dede A.D., Tournis S., Dontas I., Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014 Dec; 63(12): 1480 - 90. doi: 10.1016/j.metabol.2014.09.002.
80. Xu W., Perera S., Medich D., Fiorito G., Wagner J., Berger L.K., Greenspan S.L. Height loss, vertebral fractures, and the misclassification of osteoporosis. Bone. 2011 Feb; 48(2): 307 - 11. doi: 10.1016/j.bone.2010.09.027. Epub 2010 Sep 24.
81. Kamimura, M., Nakamura, Y., Sugino, N. et al. Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older: a cross-sectional survey. Sci Rep 6, 29199 (2016). https://doi.org/10.1038/srep29199.
82. Mikula, A.L., Hetzel, S.J., Binkley, N. et al. Validity of height loss as a predictor for prevalent vertebral fractures, low bone mineral density, and vitamin D deficiency. Osteoporos Int 28, 1659 - 1665 (2017). https://doi.org/10.1007/s00198-017-3937-z.
83. Genant H., Wu C., van Kuijk C., Nevitt M. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8(9): 1137 - 1148. doi: 10.1002/jbmr.5650080915.
84. Genant H.K., Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporosis Int. 2003; 14(3): 43 - 55.
85. Kazawa N. T2WI MRI and MRI-MDCT correlations of the osteoporotic vertebral compressive fractures. European Journal of Radiology. 2012; 81(7): 1630 - 1636. doi: 10.1016/j.ejrad.2011.04.052.
86. Baum T., Karampinos D., Liebl H., Rummeny E., Waldt S., Bauer J. High-Resolution Bone Imaging for Osteoporosis Diagnostics and Therapy Monitoring Using Clinical MDCT and MRI. CMC. 2013; 20(38): 4844 - 4852. doi: 10.2174/09298673113206660279.
87. Lenchik L., Rogers L., Delmas P., Genant H. Diagnosis of Osteoporotic Vertebral Fractures: Importance of Recognition and Description by Radiologists. American Journal of Roentgenology. 2004; 183(4): 949 - 958. doi: 10.2214/ajr.183.4.1830949.
88. Grigoryan M., Guermazi A., Roemer F., Delmas P., Genant H. Recognizing and reporting osteoporotic vertebral fractures. European Spine Journal. 2003; 12(0): S104 - S112. doi: 10.1007/s00586-003-0613-0.
89. Papadakis A., Karantanas A., Papadokostakis G., Petinellis E., Damilakis J. Can abdominal multi-detector CT diagnose spinal osteoporosis?. Eur Radiol. 2008; 19(1): 172 - 176. doi: 10.1007/s00330-008-1099-2.
90. Papadakis A., Karantanas A., Papadokostakis G., Damilakis J. Assessment of the morpho-densitometric parameters of the lumbar pedicles in osteoporotic and control women undergoing routine abdominal MDCT examinations. J Bone Miner Metab. 2010; 29(3): 352 - 358. doi: 10.1007/s00774-010-0227-7.
91. Baum T., Grande Garcia E., Burgkart R. et al. Osteoporosis imaging: effects of bone preservation on MDCT-based trabecular bone microstructure parameters and finite element models. BMC Medical Imaging. 2015; 15(1). doi: 10.1186/s12880-015-0066-z.
92. Damilakis J., Adams J., Guglielmi G., Link T. Radiation exposure in X-ray-based imaging techniques used in osteoporosis. Eur Radiol. 2010; 20(11): 2707 - 2714. doi: 10.1007/s00330-010-1845-0.
93. Kanis J.A., Harvey N.C., Cooper C. et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016 Dec; 11(1): 25. doi: 10.1007/s11657-016-0278-z.
94. Merlijn T., Swart KMA, van der Horst H.E., Netelenbos J.C., Elders PJM (2020) Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 31: 251 - 257.
95. Rubin K.H., Rothmann M.J., Holmberg T., Hoiberg M., Moller S., Barkmann R., Gluer C.C., Hermann A.P., Bech M., Gram J., Brixen K. (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 29: 567 - 578.
96. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A.; National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int. 2008 Oct; 19(10): 1395 - 408. doi: 10.1007/s00198-008-0712-1.
97. Kanis J., Johnell O., De Laet C., Jonsson B., Oden A., Ogelsby A. International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. J Bone Miner Res. 2002; 17(7): 1237 - 1244. doi: 10.1359/jbmr.2002.17.7.1237.
98. De Laet C., Van Hout B., Burger H., Weel A., Hofman A., Pols H. Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam Study. J Bone Miner Res. 2009; 13(10): 1587 - 1593. doi: 10.1359/jbmr.1998.13.10.1587.
99. Kanis J.A., Delmas P., Burckhardt P., Cooper C., Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1997; 7(4): 390 - 406. DOI: 10.1007/bf01623782.
100. Kanis J.A., McCloskey E.V., Johansson H., Cooper C., Rizzoli R., Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan; 24(1): 23 - 57. doi: 10.1007/s00198-012-2074-y.
101. Lekamwasam S., Adachi J.D., Agnusdei D., Bilezikian J., Boonen S., Borgstrom F., Cooper C., Diez Perez A., Eastell R., Hofbauer L., Kanis J.A., Langdahl B.L., Lesnyak O., Lorenc R., McCloskey E., Messina O.D., Napoli N., Obermayer-Pietsch B., Ralston S.H., Sambrook P.N., Silverman S., Sosa M., Stepan J., Suppan G., Wahl D.A., Compston J.E. for the Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Sep; 23(9): 2257 - 76. doi: 10.1007/s00198-012-1958-1.
102. Алексеева Л.И., Баранова И.А., Белова К.Ю., Ершова О.Б., Зазерская И.Е., Зоткин Е.Г., Лесняк О.М., Никитинская О.А., Рожинская Л.Я., Скрипникова И.А., Смирнов А.В., Щеплягина Л.А.: Клинические рекомендации по профилактике и ведению больных с остеопорозом. Литера; 2012: 23.
103. Никитинская О.А., Торопцова Н.В. Оценка риска переломов с использованием модели FRAX(R) (ретроспективное десятилетнее исследование) Альманах клинической медицины. 2014; 43: 50 - 55.
104. National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX(R) Implementation. Available http://www.nof.org/files/nof/public/content/resource/862/files/392.pdf. Accessed January 28, 2013
105. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011: 22: 809 - 816.
106. Kanis J.A., Johansson H., Oden A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004 Jun; 19(6): 893 - 9. DOI: 10.1359/JBMR.040134.
107. Van Staa T.P., Leufkens H.G.M., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002 Oct; 13(10): 777 - 87.
108. Ferrari S.L., Abrahamsen B., Napoli N., et al; Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018 Dec; 29(12): 2585 - 2596. doi: 10.1007/s00198-018-4650-2.
109. Leslie W.D., Johansson H., McCloskey E.V., Harvey N.C., Kanis J.A., Hans D. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. J Bone Miner Res. 2018 Nov; 33(11): 1923 - 1930. doi: 10.1002/jbmr.3538.
110. Baleanu F., Bergmann P., Hambye A.S., Dekelver C., Iconaru L., Cappelle S.I., Moreau M., Paesmans M., Karmali R., Body J.J. Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort. Int J Clin Pract. 2019 Mar 26: e13347. doi: 10.1111/ijcp.13347.
111. Johansson H., Oden A., Johnell O., Jonsson B., de Laet C., Oglesby A., McCloskey E.V., Kayan K., Jalava T., Kanis J.A. (2004) Optimization of BMD measurements to identify high risk groups for treatment-a test analysis. J Bone Miner Res 19: 906 - 913.
112. Tosteson A.N., Melton L.J., 3rd, Dawson-Hughes B., Baim S., Favus M.J., Khosla S., Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19: 437 - 447.
113. Leslie W.D., Morin S., Lix L.M., Johansson H., Oden A., McCloskey E., Kanis J..A (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23: 75 - 85.
114. Leslie W.D., Majumdar S.R., Lix L.M., Johansson H., Oden A., McCloskey E., Kanis J.A. (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23: 391 - 397.
115. Kanis J.A., Oden A., Johnell O., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 18: 1033 - 1046.
116. Kyriakos G., Vidal-Casariego A., Fernandez-Martinez M.N. et al. Impact of the NOGG and NOF guidelines on the indication of bone mineral density in routine clinical practice. J Clin Densitom. 2015 Oct - Dec; 18(4): 533 - 8. doi: 10.1016/j.jocd.2015.08.001.
117. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A. Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos Int. 2008; 19: 1395 - 1408.
118. Johansson H., Kanis J.A., Oden A., Johnell O., McCloskey E. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int (2009) 20: 1675 - 1682.
119. Johansson H., Kanis J.A., Oden A., Compston J., McCloskey E. A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int (2012) 23: 907 - 915.
120. Kanis J.A., Adams J., Borgstrom F. et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2008) 42: 4 - 15.
121. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., Black D.M. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112: 281 - 289.
122. Chen P., Miller P.D., Delmas P.D., Misurski D.A., Krege J.H. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 1785 - 1790.
123. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause. 2002: 84 - 101. doi: 10.1097/00042192-200203000-00003.
124. ISCD positions. Journal of Clinical Densitometry. 2004; 7(1).
125. Official Positions of the International Society for Clinical Densitometry. Copyright ISCD, October 2007.
126. Shepherd J.A., Blake G.M. T-scores and Z-scores. J Clin Densitom. 2007 Oct-Dec; 10(4): 349 - 50. DOI: 10.1016/j.jocd.2007.08.006.
127. Watts N.B., Leslie W.D., Foldes A.J., Miller P.D. International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitom. 2013 Oct - Dec; 16(4): 472 - 81. doi: 10.1016/j.jocd.2013.08.001.
128. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva. World Health Organ Tech Rep Ser. 1994; 843: 1 - 129.
129. Kelly T.L. Bone mineral density reference databases for American men and women. J Bone Miner Res 1990, 5 (Suppl 2): S249.
130. Hanson J. Standardization of femur BMD. J Bone Miner Res 1997, 12: 1316 e1317.
131. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Melton L.J. 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008 Mar; 42(3): 467 - 75. doi: 10.1016/j.bone.2007.11.001.
132. Nelson H.D., Haney E.M., Chou R., Dana T., Fu R., Bougatsos C. Screening for Osteoporosis: Systematic Review to Update the 2002 US Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jul. Report No.: 10-05145-EF-1.
133. Melton L.J. Chrischilles E.A., Cooper C., Lane A.W., Riggs B.L. How many women have osteoporosis. J Bone Miner Res 1993: 7: 1005 - 1010.
134. Bonnick S. Bone Densitometry in Clinical Practice. Humana Press Inc. 2004: 411.
135. McCloskey E.V., Oden A., Harvey N.C., et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and its Relationship to FRAX. J Bone Miner Res. 2016 May; 31(5): 940 - 8. doi: 10.1002/jbmr.2734.
136. Bousson V., Bergot C., Sutter B., Levitz P., Cortet B. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporosis International. 2011; 23(5): 1489 - 1501. doi: 10.1007/s00198-011-1824-6.
137. International Society for Clinical Densitometry. 2013 Official Positions - Adult. http://www.iscd.org/official-positions/2013-iscd-official-positions-adult. Ссылка активна на 12.05.2019.
138. Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535 - 1541.
139. Cummings S.R., Black D.M., Thompson D.E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077 - 2082. doi: 10.1001/jama.280.24.2077.
140. Orwoll E., Ettinger M., Weiss S., Miller P., Kendler D., Graham J., Adami S., Weber K., Lorenc R., Pietschmann P., Vandormael K., Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000 Aug 31; 343(9): 604 - 10. DOI: 10.1056/NEJM200008313430902.
141. Saag K., Emkey R., Schnitzer T. et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Obstetrical & Gynecological Survey. 1999; 54(1): 39 - 40. doi: 10.1097/00006254-199901000-00021.
142. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.N Engl J Med. 2001; 344: 333 - 340.
143. Boonen S., Orwoll E., Wenderoth D., Stoner K., Eusebio R., Delmas P. Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study. Journal of Bone and Mineral Research. 2009; 24(4): 719 - 725. doi: 10.1359/jbmr.081214.
144. Eastell R., Devogelaer J., Peel N. et al. Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. Osteoporosis International. 2000; 11(4): 331 - 337. doi: 10.1007/s001980070122.
145. Chesnut C.H. 3rd, Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gilbride J., Schimmer R.C., Delmas P.D.; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug; 19(8): 1241 - 9. Epub 2004 Mar 29.
146. Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., Reginster J.Y., Recker R.R., Hughes C., Lewiecki E.M., Felsenberg D., Delmas P.D., Kendler D.L., Bolognese M.A., Mairon N., Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res. 2005 Aug; 20(8): 1315 - 22. Epub 2005 Mar 14.
147. Recker R.R., Ste-Marie L.G., Langdahl B., Czerwinski E., Bonvoisin B., Masanauskaite D., Rowell L., Felsenberg D. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone. 2010 Mar; 46(3): 660 - 5. doi: 10.1016/j.bone.2009.11.004. Epub 2009 Nov 10.
148. Harris S., Blumentals W., Miller P. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion. 2007; 24(1): 237 - 245. doi: 10.1185/030079908x253717.
149. Black D., Delmas P., Eastell R. et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007 May 3; 356(18): 1809 - 22 DOI: 10.1056/NEJMoa067312.
150. Boonen S., Reginster J., Kaufman J. et al. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. New England Journal of Medicine. 2012; 367(18): 1714 - 1723.
151. Reid D.M., Devogelaer J.P., Saag K., Roux C., Lau C.S., Reginster J.Y., Papanastasiou P., Ferreira A., Hartl F., Fashola T., Mesenbrink P., Sambrook P.N.; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 Apr 11; 373(9671): 1253 - 63. doi: 10.1016/S0140-6736(09)60250-6.
152. Kenneth W. Lyles, Cathleen S. Colon-Emeric, M.H.Sc., Jay S. Magaziner, et al for the HORIZON Recurrent Fracture Trial* Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007; 357: 1799 - 1809.
153. McClung M., Miller P., Recknor C., Mesenbrink P., Bucci-Rechtweg C., Benhamou C. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics & Gynecology. 2009; 114(5): 999 - 1007. doi: 10.1097/aog.0b013e3181bdce0a.
154. Reid I.R., Horne A.M., Mihov B., Stewart A., Garratt E., Wong S., Wiessing K.R., Bolland M.J., Bastin S., Gamble G.D. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20; 379(25): 2407 - 2416. doi: 10.1056/NEJMoa1808082.
155. Cummings S., Martin J., McClung M. et al. Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. N Engl J Med. 2009 Aug 20; 361(8): 756 - 65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11.
156. Langdahl B., Teglbjarg C., Ho P. et al. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. The Journal of Clinical Endocrinology & Metabolism. 2015; 100(4): 1335 - 1342. doi: 10.1210/jc.2014-4079.
157. Orwoll E., Teglbjarg C., Langdahl B. et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism. 2012; 97(9): 3161 - 3169. doi: 10.1210/jc.2012-1569.
158. Saag K.G., Pannacciulli N., Geusens P., Adachi J.D., Messina O.D., Morales-Torres J., Emkey R., Butler P.W., Yin X., Lems W.F. Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019 Feb 28. doi: 10.1002/art.40874.
159. Gnant M., Pfeiler G., Dubsky P. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2015; 386(9992): 433 - 443. doi: 10.1016/s0140-6736(15)60995-3.
160. Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R., Tammela T.L., Saad F., Heracek J., Szwedowski M., Ke C., Kupic A., Leder B.Z., Goessl C.; DenosumabHALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20; 361(8): 745 - 55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.
161. Amiche M.A., Albaum J.M., Tadrous M., et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network. Osteoporos Int. 2016 Jun; 27(6): 1989 - 98. doi: 10.1007/s00198-015-3476-4.
162. Benlidayi I.C. Denosumab in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. 2018 Nov; 38(11): 1975 - 1984. doi: 10.1007/s00296-018-4106-1.
163. Yamaguchi Y., Morita T., Kumanogoh A. The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis. Rheumatol Adv Pract. 2020 Mar 13; 4(1): rkaa008. doi: 10.1093/rap/rkaa008.
164. Yanbeiy Z.A., Hansen K.E. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther. 2019 Aug 14; 13: 2843 - 2852. doi: 10.2147/DDDT.S148654.
165. Miller P., Bolognese M., Lewiecki E. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008; 43(2): 222 - 229. doi: 10.1016/j.bone.2008.04.007.
166. Mandema JW1, Zheng J., Libanati C., Perez Ruixo J.J. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. J Clin Endocrinol Metab. 2014 Oct; 99(10): 3746 - 55. doi: 10.1210/jc.2013-3795. Epub 2014 Jun 10.
167. Brown J., Prince R., Deal C. et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. Journal of Bone and Mineral Research. 2009; 24(1): 153 - 161. doi: 10.1359/jbmr.0809010.
168. Choi N.K., Solomon D.H., Tsacogianis T.N., Landon J.E., Song H.J., Kim S.C. Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res. 2016 Oct 13. doi: 10.1002/jbmr.3019.
169. Kendler D., Roux C., Benhamou C. et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2009; 25(1): 72 - 81. doi: 10.1359/jbmr.090716.
170. Tsai J., Uihlein A., Burnett-Bowie S. et al. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. J Bone Miner Res. 2014; 30(1): 39 - 45. doi: 10.1002/jbmr.2315.
171. Broadwell A., Chines A., Ebeling P.R., Franek E., Huang S., Smith S., Kendler D., Messina O., Miller P.D. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. J Clin Endocrinol Metab. 2021 Jan 23; 106(2): 397 - 409. doi: 10.1210/clinem/dgaa851. PMID: 33211870; PMCID: PMC7823314.
172. Meier C., Uebelhart B., Aubry-Rozier B., Birkhauser M., Bischoff-Ferrari H.A., Frey D., Kressig R.W., Lamy O., Lippuner K., Stute P., Suhm N., Ferrari S. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Med Wkly. 2017 Aug 16; 147: w14484. doi: 10.4414/smw.2017.14484.
173. Miller P.D., Pannacciulli N., Brown J.P., Czerwinski E., Nedergaard B.S., Bolognese M.A., Malouf J., Bone H.G., Reginster J.Y., Singer A., Wang C., Wagman R.B., Cummings S.R. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab. 2016 Aug; 101(8): 3163 - 70. doi: 10.1210/jc.2016-1801.
174. McClung M. Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies. Current Osteoporosis Reports. 2006; 4(1): 28 - 33. doi: 10.1007/s11914-006-0012-7.
175. Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза - применение моноклональных человеческих антител к RANKL (Деносумаб). Остеопороз и Остеопатии. 2011; 2: 19 - 22.
176. Neer R., Arnaud C., Zanchetta J. et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis. N Engl J Med. 2001 May 10; 344(19): 1434 - 41 DOI: 10.1056/NEJM200105103441904.
177. Orwoll E., Scheele W., Paul S. et al. The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis. J Bone Miner Res. 2003; 18(1): 9 - 17. doi: 10.1359/jbmr.2003.18.1.9.
178. Saag K., Shane E., Boonen S. et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2007 Nov 15; 357(20): 2028 - 39 DOI: 10.1056/NEJMoa071408.
179. Saag K., Zanchetta J., Devogelaer J. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism. 2009; 60(11): 3346 - 3355. doi: 10.1002/art.24879.
180. Liu C.L., Lee H.C., Chen C.C., Cho D.Y. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clin Invest Med. 2017; 40(3): E146 - E157. doi: 10.25011/cim.v40i3.28394.
181. Wang Y.K., Qin S.Q., Ma T., Song W., Jiang R.Q., Guo J.B., Li K., Zhang Y.M. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017; 96(21): e6970. doi: 10.1097/MD.0000000000006970.
182. Kendler D.L., Marin F., Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018 Jan 20; 391(10117): 230 - 240. doi: 10.1016/S0140-6736(17) 32137-2
183. Body J., Gaich G., Scheele W. et al. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 2002; 87(10): 4528 - 4535. doi: 10.1210/jc.2002-020334.
184. Hadji P., Zanchetta J., Russo L. et al. Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures. Bone. 2011; 48: S82 - S83. doi: 10.1016/j.bone.2011.03.108.
185. Miller P.D., Shergy W.J., Body J., Chen P., Rohe M.E., Krege J.H.: Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate.
186. European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007.
187. European Medicines Agency: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013.
188. European Medicines Agency: Protelos/Osseor (strontium ranelate) to remain available but with futher restrictions 15 April 2014 EMA 235924/2014. J Rheumatology. 2005; 32: 1556 - 1562.
189. O'Donnel S., Cranney A., Wells G.A., Adachi J., Reginster J.Y. (2008) Strontium ranelate for preventing and treating osteoporosis. The Cochrane Library, Issue 4.
190. Adler R., El-Hajj Fuleihan G., Bauer D. et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016; 31(1): 16 - 35. doi: 10.1002/jbmr.2708.
191. Black D.M., Boonen S., Cauley J.A., Cummings S.R., Lippuner K., Leung P.C., Martinez RLM, Ruzycky M.E., Eastell R. (2012a) Erratum: The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the horizon-pivotal fracture trial (PFT). J Bone Miner Res 27(12): 2612.
192. Black D.M., Reid I.R., Cauley J.A., Cosman F., Leung P.C., Lakatos P., Lippuner K., Cummings S.R., Hue T.F., Mukhopadhyay A., Tan M., Aftring R.P., Eastell R. (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30(5): 934 - 944.
193. Dennison E.M., Cooper C., Kanis J.A., Bruyere O., Silverman S., McCloskey E., Abrahamsen B., Prieto-Alhambra D., Ferrari S.; IOF Epidemiology/Quality of Life Working Group. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int. 2019 Jun 7. doi: 10.1007/s00198-019-05002-w.
194. Bone H.G., Wagman R.B., Brandi M.L., Brown J.P., Chapurlat R., Cummings S.R., Czerwinski E., Fahrleitner-Pammer A., Kendler D.L., Lippuner K., Reginster J.Y., Roux C., Malouf J., Bradley M.N., Daizadeh N.S., Wang A., Dakin P., Pannacciulli N., Dempster D.W., Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017 5(7): 513 - 23.
195. Bone H.G., Bolognese M.A., Yuenn C.K., Kendler D.L., Miller P.D., Yang Y.C., Grazette L., Martin J.S., Gallagher J.C. (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4): 972 - 980.
196. Bone H.G., Chapurlat R., Brandi M.L., et al. (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab 98(11): 4483 - 4492.
197. Anagnostis P., Paschou S.A., Mintziori G., Ceausu I., Depypere H., Lambrinoudaki I., Mueck A., Perez-Lopez F.R., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Tremollieres F.A., Goulis DG Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas, 2017, 101; 23030.
198. Белая Ж.Е., Bilezikian J.P., Ершова О.Б., и др. Возможности длительной терапии постменопаузального остеопороза: обзор результатов клинических исследований деносумаба и резолюция совета экспертов российской ассоциации по остеопорозу (РАОП). Ж. Остеопороз и Остеопатии, 2018, Том 21, стр. 4 - 9.
199. Brown J., Roux C., Torring O. et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res. 2013; 28(4): 746 - 752. doi: 10.1002/jbmr.1808.
200. Popp A., Zysset P., Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab - from clinic and biomechanics. Osteoporosis International. 2015; 27(5): 1917 - 1921. doi: 10.1007/s00198-015-3458-6.
201. Tsourdi E., Langdahl B., Cohen-Solal M., Aubry-Rozier B., Eriksen E.F., Guanabens N., Obermayer-Pietsch B., Ralston S.H., Eastell R., Zillikens M.C. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017; 105: 11 - 17.
202. Tsourdi Elena, Bente Langdahl, Martine Cohen-Solal, Berengere Aubry-Rozier, Erik Fink Eriksen, Nuria Guanabens, Barbara Obermayer-Pietsch, Stuart H Ralston, Richard Eastell, M Carola Zillikens. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS Review. Bone, 2017 Dec; 105: 11 - 17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5.
203. Tsourdi E., Zillikens M.C., Meier C., Body J.J., Rodriguez E.G., Anastasilakis A.D., Abrahamsen B., McCloskey E., Hofbauer L.C., Guanabens N., Obermayer-Pietsch B., Ralston S.H., Eastell R., Pepe J., Palermo A., Langdahl B. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020 Oct 26: dgaa756. doi: 10.1210/clinem/dgaa756. Online ahead of print.PMID: 33103722.
204. Koldkjar Solling A., Harslof T., Kaal A., Rejnmark L., Langdahl B. Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporosis International. 2016. doi: 10.1007/s00198-016-3535-5.
205. Leder B.Z., Tsai J.N., Uihlein A.V., Wallace P.M., Lee H., Neer R.M., Burnett-Bowie SAM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet 386(9999): 1147 - 1155.
206. Ebina K., Hashimoto J., Kashii M., Hirao M., Kaneshiro S., Noguchi T., Tsukamoto Y., Yoshikawa H. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab. 2017 Jan; 35(1): 91 - 98. doi: 10.1007/s00774-015-0731-x.
207. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., Rosen C.J. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000 Jun; 85(6): 2129 - 34. doi: 10.1210/jcem.85.6.6614.
208. Diez-Perez A., Adachi J.D., Agnusdei D., Bilezikian J.P., Compston J.E., Cummings S.R., Eastell R., Eriksen E.F., Gonzales-Macies J., Liberman U.A., Wahl D.A., Seeman E., Kanis J.A., Cooper C.: Treatment failure in osteoporosis. Osteoporosis Int. 2012; (23): 2769 - 2774.
209. Gaal J., Bender T., Varga J. et al. Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study. Rheumatol Int. 2009; 30(1): 25 - 31. doi: 10.1007/s00296-009-0892-9.
210. Harris S.T., Watts N.B., Genant H.K. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282: 1344 - 1352.
211. Reginster J., Minne H., Sorensen O. et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis. Osteoporosis International. 2000; 11(1): 83 - 91. doi: 10.1007/s001980050010.
212. Meunier P., Roux C., Seeman E. et al. The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women With Postmenopausal Osteoporosis. N Engl J Med. 2004 Jan 29; 350(5): 459 - 68 DOI: 10.1056/NEJMoa022436.
213. British Orthopaedic Association and British Geriatrics Society. The care of patients with fragility fracture. 2007: 15 - 50.
214. Griffiths R., Alper J., Beckingsale A. et al. Management of proximal femoral fractures 2011. Anaesthesia. 2011; 67(1): 85 - 98. doi: 10.1111/j.1365-2044.2011.06957.x.
215. Загородний Н.В., Голухов Г.Н., Волна А.А. и др. Диагностика и лечение переломов проксимального отдела бедра у лиц пожилого и старческого возраста. Метод. Рекомендации. Москва, РУДН, 2012.
216. Roche J. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005; 331(7529) 1374-0. doi: 10.1136/bmj.38643.663843.55.
217. Kates S., Mendelson D., Friedman S. Co-managed care for fragility hip fractures (Rochester model). Osteoporosis International. 2010; 21(S4): 621 - 625. doi: 10.1007/s00198-010-1417-9.
218. Silverman S.L., Kupperman E.S., Bukata S.V., Members of IOF Fracture Working Group Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group Osteoporos Int (2016) 27: 2197 - 2206 DOI 10.1007/s00198-016-3513-y.
219. Oliver D., Connelly J., Victor C. et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007; 334(7584): 82 - 82. doi: 10.1136/bmj.39049.706493.55.
220. Schmidt K., Hubscher M., Vogt L., et al. Influence of spinal orthosis on gait and physical functioning in women with postmenopausal osteoporosis // Der Orthopade. - 2012. - Vol. 41. - No 3. - P 200 - 205.
221. Pfeifer M., Begerow B., Minne H.W. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil. 2004; 83: 177 - 186.
222. Yuan Zhe Jin, Jae Hyup Lee Effect of Brace to Osteoporotic Vertebral Fracture: A Meta-Analysis // J Korean Med Sci 2016; 31: 1641 - 1649.
223. Valentin G.H., Pedersen L.N. Maribo T. Wearing an active spinal orthosis improves back extensor strength in women with osteoporotic vertebral fractures // Prosthetics and orthotics international. - 2014. - Vol. 38. - No 3. - P. 232 - 238.
224. Matussek J., Boluki D., Fussel S., Grifka. Orthotic methods for osteoporosis and osteoporotic vertebral fracture. J. Orthopade. 2010 Apr 39(4): 387 - 96. [Article in German] doi: 10.1007/s00132-010-1596-2.
225. Shariatzadeh H., Modaghegh B.S., M.D., Mirzaei A. The Effect of Dynamic Hyperextension Brace on Osteoporosis and Hyperkyphosis Reduction in Postmenopausal Osteoporotic Women. Arch Bone Jt Surg. 2017 May; 5(3): 181 - 185.
226. Snow-Harter C., Bouxsein M.L., Lewis B.T., Carter D.R., Marcus R. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J Bone Miner Res. 1992; 7: 761 - 769.
227. Vainionpaa A., Korpelainen R., Leppaluoto J., Jamsa T. Effects of high-impact exercise on bone mineral density: a randomized controlled trial in premenopausal women. Osteoporos Int. 2005; 16(2): 191 - 7.
228. Yu H.S., Kim J.J., Kim H.W., Lewis M.P., Wall I. Impact of mechanical stretch on the cell behaviors of bone and surrounding tissues. J Tissue Eng. 2016; 7: 2041731415618342. doi: 10.1177/2041731415618342.
229. Kelley G., Kelley K., Tran Z. Exercise and Lumbar Spine Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Individual Patient Data. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2002; 57(9): M599 - M604. doi: 10.1093/gerona/57.9.m599.
230. Michael Y., Whitlock E., Lin J., Fu R., O'Connor E., Gold R. Primary Care-Relevant Interventions to Prevent Falling in Older Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2010; 153(12): 815. doi: 10.7326/0003-4819-153-12-201012210-00008.
231. Howe T.E., Shea B., Dawson L.J., Downie F., Murray A., Ross C., Harbour R.T., Caldwell L.M., Creed G. (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011; (7): CD000333. doi: 10.1002/14651858.CD000333.pub2.
232. Sherrington C., Whitney J., Lord S., Herbert R., Cumming R., Close J. Effective Exercise for the Prevention of Falls: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society. 2008; 56(12): 2234 - 2243. doi: 10.1111/j.1532-5415.2008.02014.x.
233. Howe T.E., Rochester L., Neil F., Skelton D.A., Ballinger C. (2011) Exercise for improving balance in older people. Cochrane Database Syst Rev. 2011 Nov 9; (11): CD004963. doi: 10.1002/14651858.CD004963.pub3.
234. Li W., Chen Y., Yang R., Tsauo J. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis. Clinical Rehabilitation. 2009; 23(10): 888 - 896. doi: 10.1177/0269215509339002.
235. Smith E., Carroll A. Bone mineral density in adults disabled through acquired neurological conditions: a review. J Clin Densitom. 2011; 14(2): 85 - 94. doi: 10.1016/j.jocd.2010.12.002
236. Dawson-Hughes B., Mithal A., Bonjour J. et al. IOF position statement: vitamin D recommendations for older adults. Osteoporosis International. 2010; 21(7): 1151 - 1154. doi: 10.1007/s00198-010-1285-3.
237. The DIPART Group. Patient level pooled analysis of 68500 patients from seven major vitamin D fracture prevention in US and Europe. BMJ. 2010; 340: b5463.
238. Tripkovic L., Lambert H., Hart K., Smith C.P., Bucca G., Penson S., Chope G., Hypponen E., Berry J., Vieth R., Lanham-New S. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012 Jun; 95(6): 1357 - 64. doi: 10.3945/ajcn.111.031070. Epub 2012 May 2. PMID: 22552031; PMCID: PMC3349454.
239. Hassan A.B., Hozayen R.F., Alotaibi R.A., Tayem Y.I. Therapeutic and maintenance regimens of vitamin D3 supplementation in healthy adults: A systematic review. Cell Mol Biol (Noisy-le-grand). 2018 Nov 30; 64(14): 8 - 14. PMID: 30511630.
240. Kearns M.D., Alvarez J.A., Tangpricha V. Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review. Endocr Pract. 2014 Apr; 20(4): 341 - 51. doi: 10.4158/EP13265.RA. PMID: 24246341; PMCID: PMC4128480.
241. Tabatabaeizadeh S.A., Avan A., Bahrami A., Khodashenas E., Esmaeili H., Ferns G.A., Abdizadeh M.F., Ghayour-Mobarhan M. High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation: Reductions in High Sensitivity C-Reactive Protein Level and Neutrophil to Lymphocyte Ratio (NLR) Distribution. J Cell Biochem. 2017 Dec; 118(12): 4317 - 4322. doi: 10.1002/jcb.26084. Epub 2017 Jun 9. PMID: 28425575.
242. Esfandiari A., Pourghassem Gargari B., Noshad H., Sarbakhsh P., Mobasseri M., Barzegari M., Arzhang P. The effects of vitamin D3 supplementation on some metabolic and inflammatory markers in diabetic nephropathy patients with marginal status of vitamin D: A randomized double blind placebo controlled clinical trial. Diabetes Metab Syndr. 2019 Jan - Feb; 13(1): 278 - 283. doi: 10.1016/j.dsx.2018.09.013. Epub 2018 Sep 12. PMID: 30641712.
243. Dalle Carbonare L., Valenti M.T., Del Forno F., Piacentini G., Pietrobelli A. Vitamin D Daily versus Monthly Administration: Bone Turnover and Adipose Tissue Influences. Nutrients. 2018 Dec 6; 10(12): 1934. doi: 10.3390/nu10121934. PMID: 30563215; PMCID: PMC6315364.
244. Venugopal Y., Hatta SFWM, Musa N., Rahman S.A., Ratnasingam J., Paramasivam S.S., Lim L.L., Ibrahim L., Choong K., Tan A.T., Chinna K., Chan S.P., Vethakkan S.R. Maintenance vitamin D3 dosage requirements in Chinese women with post menopausal osteoporosis living in the tropics. Asia Pac J Clin Nutr. 2017 May; 26(3): 412 - 420. doi: 10.6133/apjcn.042016.10. PMID: 28429905.
245. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., Дзеранова Л.К., Каронова Т.Л., Ильин А.В., Мельниченко Г.А., Дедов И.И. Клинические рекомендации Российской Ассоциации Эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016. Т. 62. N 4. С. 60 - 84
246. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J.: Human serum 25-hydroxychole-calciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003; 77(1): 204 - 10.
247. Broe K., Chen T., Weinberg J., Bischoff-Ferrari H., Holick M., Kiel D. A Higher Dose of Vitamin D Reduces the Risk of Falls in Nursing Home Residents: A Randomized, Multiple-Dose Study. Journal of the American Geriatrics Society. 2007; 55(2): 234 - 239. doi: 10.1111/j.1532-5415.2007.01048.x.
248. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.
249. Химический состав пищевых продуктов, используемых в Российской Федерации доступен по ссылке: http://web.ion.ru. Ссылка активна на 05.05.2016.
250. Boonen S., Bischoff-Ferrari H., Cooper C. et al. Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence. Calcified Tissue International. 2006; 78(5): 257 - 270. doi: 10.1007/s00223-005-0009-8.
251. Tang B.M., Eslick C.D., Nowson C., et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older; a meta-analysis. Lancet. 2007; 370: 657 - 66.
252. Richy F., Dukas L., Schacht E. Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls: A Comparative Meta-Analysis. Calcified Tissue International. 2008; 82(2): 102 - 107. doi: 10.1007/s00223-008-9102-0.
253. Del Valle E., Negri A.L., Fradinger E., Canalis M., Bevione P., Curcelegui M., Bravo M., Puddu M., Marini A., Ryba J., Peri P., Rosa Diez G., Sintado L., Gottlieb E. Weekly high-dose ergocalciferol to correct vitamin D deficiency/insufficiency in hemodialysis patients: A pilot trial. Hemodial Int. 2014. doi: 10.1111/hdi.12209.
254. Mager D.R., Jackson S.T., Hoffmann M.R., Jindal K., Senior P.A. "Vitamin D supplementation and bone health in adults with diabetic nephropathy: the protocol for a randomized controlled trial". BMC Endocr Disord. 2014; 14: 66. doi: 10.1186/1472-6823-14-66.
255. Baber R., Panay N., Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109 - 150. doi: 10.3109/13697137.2015.1129166.
256. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321 - 333.
257. Ettinger B., Ensrud K., Wallace R. et al. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial. Obstetrics & Gynecology. 2004; 104(3): 443 - 451. doi: 10.1097/01.aog.0000137833.43248.79.
258. T.J. de Villiers, J.E. Hall, J.V. Pinkerton, S. Cerdas Perez, M. Rees, C. Yang, D.D. Pierroz Revised global Consensus Statement on Menopausal Hormone Therapy. J. Climacteric 2016 19: 4; 313 - 315.
259. McLellan A., Reid D., Forbes K., et al. Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland (CEPS 99/03): NHS Quality Improvement Scotland. 2004.
260. Akesson K., Marsh D., Mitchell P.J. et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 2013; 24 (8): 2135 - 2152.
261. Hagino H., Sawaguchi T., Endo N., et al. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 2012; 90: 14 - 21.
262. Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011; 22 Suppl 3: 457 - 60.
263. Nakayama A., Major G., Holliday E., Attia J., Bogduk N. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int. 2016; 27(3): 873 - 9.
264. Marsh D., Akesson K., Beaton D.E. et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int. 2011; 22: 2051 - 2065.
265. Ganda K., Mitchell P.J., Seibel M.J. Chapter 3 - Models of Secondary Fracture Prevention: Systematic Review and Metaanalysis of Outcomes. Secondary Fracture Prevention. An International Perspective. 2019. P. 33 - 62.
266. Ganda K., Puech M., Chen J.S., Speerin R., Bleasel J., Center J.R., et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. OsteoporosInt 2013; 24(2): 393 - 406.
267. Huntjens K.M., van Geel T.A., van den Bergh J.P., et al. Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am. 2014; 96(4): e29.
268. Hawley S., Javaid M.K., Prieto-Alhambra D., et al. Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing. 2016; 45(2): 236 - 42.
269. Majumdar S.R., Lier D.A., Rowe B.H. et al. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. Osteoporos Int. 2011; 22 (6): 1799 - 1808.
270. McLellan A.R., Wolowacz S.E., Zimovetz E.A. et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011; 22: 2083 - 2098.
271. Reginster J.Y., Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90: 2816 - 2822.
272. Thompson K. Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis. Molecular Pharmacology. 2006; 69(5): 1624 - 1632. doi: 10.1124/mol.105.020776.
273. Dunford J., Rogers M., Ebetino F., Phipps R., Coxon F. Inhibition of Protein Prenylation by Bisphosphonates Causes Sustained Activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res. 2006; 21(5): 684 - 694. doi: 10.1359/jbmr.060118.
274. U.S. Food and Drug Administration. Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment. Posted 09/01/2011. Доступно по http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270464.htm. Ссылка активна на 12.05.2019.
275. Khosla S., Burr D., Cauley J. et al. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22(10): 1479 - 1491. doi: 10.1359/jbmr.0707onj.
276. Marie P. Signaling Pathways Affecting Skeletal Health. Current Osteoporosis Reports. 2012; 10(3): 190 - 198. doi: 10.1007/s11914-012-0109-0.
277. Tashjian AChabner B. Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1-34 in the Treatment of Osteoporosis in Men and Postmenopausal Women. J Bone Miner Res. 2002; 17(7): 1151 - 1161. doi: 10.1359/jbmr.2002.17.7.1151.
278. Vahle J., Sato M., Long G. et al. Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety. Toxicologic Pathology. 2002; 30(3): 312 - 321. doi: 10.1080/01926230252929882.
279. Miller P., Schwartz E., Chen P., Misurski D., Krege J. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International. 2006; 18(1): 59 - 68. doi: 10.1007/s00198-006-0189-8.
280. Nielsen S., Slosman D., Sorensen O. et al. Influence of Strontium on Bone Mineral Density and Bone Mineral Content Measurements by Dual X-Ray Absorptiometry. Journal of Clinical Densitometry. 1999; 2(4): 371 - 379. doi: 10.1016/s1094-6950(06) 60402-2.
281. Recker R., Marin F., Ish-Shalom S. et al. Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis*. Journal of Bone and Mineral Research. 2009; 24(8): 1358 - 1368. doi: 10.1359/jbmr.090315.
- Гражданский кодекс (ГК РФ)
- Жилищный кодекс (ЖК РФ)
- Налоговый кодекс (НК РФ)
- Трудовой кодекс (ТК РФ)
- Уголовный кодекс (УК РФ)
- Бюджетный кодекс (БК РФ)
- Арбитражный процессуальный кодекс
- Конституция РФ
- Земельный кодекс (ЗК РФ)
- Лесной кодекс (ЛК РФ)
- Семейный кодекс (СК РФ)
- Уголовно-исполнительный кодекс
- Уголовно-процессуальный кодекс
- Производственный календарь на 2025 год
- МРОТ 2024
- ФЗ «О банкротстве»
- О защите прав потребителей (ЗОЗПП)
- Об исполнительном производстве
- О персональных данных
- О налогах на имущество физических лиц
- О средствах массовой информации
- Производственный календарь на 2024 год
- Федеральный закон "О полиции" N 3-ФЗ
- Расходы организации ПБУ 10/99
- Минимальный размер оплаты труда (МРОТ)
- Календарь бухгалтера на 2024 год
- Частичная мобилизация: обзор новостей